[Autologous stem cell transplantation in the treatment of primary systemic amyloidosis].
Primary systemic amyloidosis is a plasma cell dyscrasia resulting multiorgan failure and death. The optimal treatment method is unknown. Current status of therapy for primary amyloidosis based on has been publication analysis. Treatment options for primary amyloidosis are similar to multiple myleoma therapy. Treatment of primary amyloidosis should be based on risk factors analysis. In selected patients high-dose therapy and autologous stem cell transplantation has been associated with higher response rate than standard chemotherapy However, autologous transplantation for primary amyloidosis remains controversial because of high treatment-related mortality. Novel non-transplant methods for primary amyloidosis therapy are highly effective. Early and detailed diagnosis and treatment based on risk factors can influence survival in group of patients with systemic primary amyloidosis.
Gil
Lidia
L
University of Medical Sciences, Department of Hematology and Neoplasmatic Diseases of Hematopoiesis, Poznan, Poland. lidia.gil@sk1.am.poznan.pl
Komarnicki
Mieczysław
M
D000328:Adult; D000686:Amyloidosis / Q000175:diagnosis / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation / Q000401:mortality; D006801:Humans; D008875:Middle Aged; D019653:Myeloablative Agonists / Q000627:therapeutic use; D012307:Risk Factors; D015996:Survival Rate
D019653:Myeloablative Agonists